ChineseChina UKUK DeutschlandDeutschland FranceFrance РоссияРоссия 한국한국 ไทยไทย Việt NamViệt Nam العربيةالعربية ҚазақстанҚазақстан EspañaEspaña MyanmarMyanmar DaiDai

Linking China’s Premium Healthcare · Serving Global Health Needs

Breaking down language, channel and process barriers in cross-border care — making the best doctors your personal doctors.
300 Grade-A partner hospitals · 3,000+ leading experts · one-stop service across all specialties

One-Stop Medical Care in China

  • International flights · Airport pickup · Nearby hotels
  • Multilingual interpreters · Full medical escort
  • Expert matching · Hospital fast-track
  • Full-cycle treatment · Post-op follow-up
Sign in

Anti-MDA5 is associated with rapidly progressive interstitial lung disease

MDA5 Accompanied Rapid Progressive Interstitial Pneumonia is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multisystemic stress. Early identification and standardization of clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.

The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of rapidly progressive interstitial pulmonary disease associated with MDA5 require individualized development, typically including multidimensional management of drug therapy, rehabilitation interventions, periodic follow-up, etc. In recent years, with the development of targeted therapy, immune-regulatory therapy, and precision medicine, many previously difficult-to-treat autoimmune and rheumatoid immune diseases have been significantly improved.

Therapeutic efficacy and adverse reactions need to be closely monitored throughout the treatment process, and timely adjusted according to changing conditions. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of rapidly progressive interstitial pulmonary disease associated with MDA5. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1.

Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3. Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4.

Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.